It’s a historic moment for Novartis. Following the Sandoz spin-off in October and capping a multi-year transformation, we’ve entered our next era as an innovative medicines company. In this new chapter, our commitment to our purpose of reimagining medicine to improve and extend peoples’ lives remains unwavering.
We’re focusing our energy on disease areas where there is significant need for new treatments and where we have deep expertise and capabilities. We’re also building on our strengths in advanced new technology platforms – radioligand therapy, RNA therapeutics and gene and cell therapy – that will help us deliver the next generation of medicines for patients.